NL-OMON43028已完成不适用
A Phase I, Open-Label Study to Investigate the Pharmacodynamics and Pharmacokinetics of Etonogestrel (ENG) and 17*-Estradiol (E2) in Healthy Young Adult Women Following Administration of MK-8342B (ENG-E2, 125/300 *g/day) Vaginal Ring for an Extended Period of Time - MK-8342B
Merck Sharp & Dohme (MSD)0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Healthy adult female subjects, 18-35 years of age, inclusive, at screening.
- •2. Continuous non-smokers who have not used nicotine-containing products for at least
- •3 months prior to ENG-E2 vaginal ring insertion.
- •3. Body mass index (BMI) * 18.5 and * 30.0 kg/m2, at screening and prior to ENG-E2 vaginal ring insertion.
- •4. Has good visibility of both ovaries upon ultrasonography at screening.
- •5. Subjects not using hormonal contraceptives should have regular menstrual cycles ranging from * 21 to * 35 days in length in the 3 months prior to screening.
- •6. Has ability to ovulate as determined by vaginal ultrasound scan measurements (i.e., measurement of Max FD and double-layer endometrial thickness) during the pre-treatment screening period. Vaginal ultrasound scan measurements will be performed 9 days (± 1) after the start of the last menstruation or withdrawal bleeding and every 3 days ± 1 day onwards until ovulation is observed, during the pre-treatment screening period. After ovulation, the subject must have P levels > 16 nmol/L on two subsequent occasions within 5 days (time of ovulation determined by vaginal ultrasound scan measurement).
- •7. Medically healthy with no clinically significant abnormalities in medical history, physical and gynecological examination, laboratory profiles, or vital signs, as judged by the Investigator.
- •8. If sexually active, subject should use a non-hormonal IUD or if she or her partner is not surgically sterilized, agrees to have her male partner use a male condom without spermicide from the time of screening and throughout completion of the study (including the follow-up period).
- •9. A normal cervical Pap (Papanicolaou) test (Pap <3) within 24 months of screening (first visit) should be documented at the time of screening (first visit); subjects who do not have documentation of normal cervical Pap test within 24 months of screening (first visit) must have a cervical Pap test performed at screening with a normal result. 10. Subject must understand the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol and provides written informed consent for the trial, including for Future Biomedical Research.
排除标准
- •1. Subject is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.
- •2. History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the Investigator.
- •3. History of any illness that, in the opinion of the Investigator, might confound the results of the study or poses an additional risk to the subject by their participation in the study.
- •4. History or presence of alcoholism or drug abuse within the past 2 years prior to screening.
- •5. History or presence of hypersensitivity or idiosyncratic reaction to the study drug or related compounds.
- •6. History or presence of: Venous thromboembolic events (VTE), arterial thromboembolic events (ATE), and other major adverse cardiovascular events (MACE) (e.g., myocardial infarction, cerebral vascular accident); headaches with focal neurological symptoms or migraine headaches with aura; breast cancer or undiagnosed breast nodules; hypertension; transient ischemic attacks; liver tumors or liver disease; jaundice with previous use of oral contraceptives or past pregnancy; diabetes; pancreatitis or severe hypertriglyceridemia; carcinoma of the endometrium or other known or suspected estrogen or progestogen dependent neoplasia; cervical cancer.
- •7. Positive pregnancy test or lactating.
- •8. Abnormal cervical Pap test within 24 months prior to screening (first visit).
- •9. Within the past 6 months prior to screening, has had undiagnosed (unexplained) abnormal vaginal bleeding or any abnormal bleeding that is expected to recur during the study (e.g., bleeding from cervical polyp, bleeding after sex).
- •10. Has stage 4 pelvic organ prolapse (1 cm beyond introitus) or lesser degrees of prolapsed with a history of difficulty retaining tampons, vaginal rings, or other products within the vagina.
- •11. Clinically significant abnormalities of the genital organs as determined by gynecological examination and based on the Investigator*s judgment.
- •12. Has gonorrhea, chlamydia, or trichomonas or symptomatic vaginitis/cervicitis. Subjects may be rescreened 3 weeks after completing treatment for these conditions.
- •13. Positive results for the urine drug and/or alcohol breathalyzer screen at screening or on Day 1.
- •14. Drink alcohol in excess of 14 units per week, with one unit = 125 mL of wine or 284 mL of beer or 25 mL of 45% alcohol.
- •15. Positive urine cotinine at screening and Day 1 (threshold >100 ng/mL). Note: subjects may be retested if positive.
- •16. Positive results at screening for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV).
- •17. Unable to refrain from or anticipates the use of any treatment listed in Table 1 of the protocol
- •18. Hemoglobin level below 11 g/dL at screening.
- •19. Blood or plasma donation (* 500 mL) within 60 days prior to screening.
- •20. Donation of bone marrow within the last 6 months prior to screening.
- •21. Is working at or has an immediate family member (spouse or children) who works at the investigational site or is a Sponsor staff member directly involved with this trial.
- •22. Participation in another clinical trial within 30 days prior to screening. The 30-day window will be derived from the date of the last blood collection or last dosing, whichever is later, in the previous study to the screening visit of the current study
研究者
相似试验
进行中（未招募）
1 期
Research done in healthy human volunteers to Investigate how the MK-8342B (ENG-E2, 125/300 µg/day) Vaginal Ring behaves in and influences the body of female Postmenarcheal Adolescents and Healthy Female Adults.Hormonal contraception and primary dysmenorrhea in woman seeking contraception.MedDRA version: 19.0Level: LLTClassification code 10073728Term: Hormonal contraceptionSystem Organ Class: 100000004865EUCTR2015-005284-16-ATMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
撤回
不适用
A Phase I, open-label study to investigate the pharmacokinetics of GLPG2451 given as two doses of a capsule formulation in healthy subjectsCystic fibrosismucoviscidosisNL-OMON45502Galapagos SAS12
已完成
1 期
Pharmacokinetics of Miist Nicotine Inhaler in healthy smokersSmoking cessationMental Health - AddictionACTRN12623001317684Miist Therapeutics South Pty Ltd10
已完成
不适用
A Phase I, open-label trial to investigate the pharmacokinetic interaction between TMC125 and two antifungal agents (fluconazole and voriconazole), all at steady-state in healthy subjects.AIDSHIV10021460NL-OMON32571Tibotec Pharmaceuticals Ltd, EastGate Village, Eastgate, Little Island, CO Cork, Ireland, In Nederland vertegenwoordigd door Janssen-Cilag B.V.18
进行中（未招募）
1 期
A PROSPECTIVE, OPEN-LABEL STUDY TO ASSESS THE PHARMACOKINETICS, SAFETY & EFFICACY OF ANIDULAFUNGIN WHEN USED TO TREAT CHILDREN WITH INVASIVE CANDIDIASIS, INCLUDING CANDIDEMIA - NDEUCTR2008-004150-32-ITPFIZER60